Clinical Trials Directory

Trials / Completed

CompletedNCT01093664

Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02

Phase IB Follow-up Study to Assess a Boost Immunization With AFFITOPE AD02 With Regard to Safety/Tolerability, Immunological and Clinical Activity in Alzheimer Patients Who Have Received the Vaccine Within the Clinical Study AFF002

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Affiris AG · Industry
Sex
All
Age
50 Years – 85 Years
Healthy volunteers
Not accepted

Summary

This is a phase IB follow-up study to assess a boost immunization with AFFITOPE AD02 with regard to safety/tolerability, immunological and clinical activity in Alzheimer patients who have received the vaccine within the clinical study AFF002.

Conditions

Interventions

TypeNameDescription
BIOLOGICALAFFITOPE AD02s.c. injection

Timeline

Start date
2009-10-01
Primary completion
2010-07-01
Completion
2010-07-01
First posted
2010-03-26
Last updated
2010-10-19

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT01093664. Inclusion in this directory is not an endorsement.

Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02 (NCT01093664) · Clinical Trials Directory